Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoff Hale

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 13, 2005
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five yearsChristopher J E Watson, J Andrew Bradley, Peter J Friend, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 4, 2010
A novel strategy to reduce the immunogenicity of biological therapiesJennifer Somerfield, Grant A Hill-Cawthorne, Andrew Lin, et al.
Journal of Virology|September 15, 2005
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virusRichard Stebbings, Neil Berry, Herman Waldmann, et al.
Lancet (London, England)|June 7, 2005
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs, Ann Hunter, Rajesh Chopra, et al.
Blood|December 17, 2009
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patientsBart Keymeulen, Sophie Candon, Samira Fafi-Kremer, et al.
The Veterinary Record|January 27, 2019
Tackling bovine TBMark Jones, Fiona Dalzell, Richard Edwards, et al.
Blood|May 31, 2002
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionSuparno Chakrabarti, Stephen Mackinnon, Raj Chopra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaSudhir Tauro, Charles Craddock, Karl Peggs, et al.
Lancet (London, England)|September 5, 2009
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 studyKarin C Straathof, Kanchan Rao, Matthias Eyrich, et al.
Blood|July 1, 2010
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionRonjon Chakraverty, Guillermo Orti, Michael Roughton, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 13, 2005
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five yearsChristopher J E Watson, J Andrew Bradley, Peter J Friend, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 4, 2010
A novel strategy to reduce the immunogenicity of biological therapiesJennifer Somerfield, Grant A Hill-Cawthorne, Andrew Lin, et al.
Journal of Virology|September 15, 2005
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virusRichard Stebbings, Neil Berry, Herman Waldmann, et al.
Lancet (London, England)|June 7, 2005
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs, Ann Hunter, Rajesh Chopra, et al.
Blood|December 17, 2009
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patientsBart Keymeulen, Sophie Candon, Samira Fafi-Kremer, et al.
The Veterinary Record|January 27, 2019
Tackling bovine TBMark Jones, Fiona Dalzell, Richard Edwards, et al.
Blood|May 31, 2002
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionSuparno Chakrabarti, Stephen Mackinnon, Raj Chopra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaSudhir Tauro, Charles Craddock, Karl Peggs, et al.
Lancet (London, England)|September 5, 2009
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 studyKarin C Straathof, Kanchan Rao, Matthias Eyrich, et al.
Blood|July 1, 2010
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionRonjon Chakraverty, Guillermo Orti, Michael Roughton, et al.
Pageof 6